Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ELI 002

Next Previous
Search
Drug Profile

ELI 002

Alternative Names: AMP KRAS; AMP-CpG; Amph-CpG-7909; Amphiphile mKRAS vaccine; Amphiphile-CpG; ELI-002; ELI-002 2P; ELI-002 7P; VED-002

Latest Information Update: 29 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Elicio Therapeutics
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Adenocarcinoma; Cholangiocarcinoma; Colorectal cancer; Gallbladder cancer; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer

Most Recent Events

  • 22 Jan 2025 Elicio Therapeutics announces intention to file a Biologics License Application (BLA) to the US FDA for ELI 002
  • 22 Jan 2025 Elicio Therapeutics plans a phase III trial for ELI 002
  • 22 Jan 2025 Elicio Therapeutics receives supportive feedback in an End of phase I Type B meeting with the US FDA for ELI 002

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top